학술논문

Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL
Document Type
Article
Source
In Blood 1 December 2022 140(22):2348-2357
Subject
Clinical Trials and Observations
Lymphoid Neoplasia
Language
ISSN
0006-4971